000			02986na a2200253 4500
003			H12O
005			20180113071256.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91206 _aAyala Díaz, Rosa María _eHematología y Hemoterapia
100			_91015 _aGilsanz Rodríguez, Florinda _eHematología y Hemoterapia
100			_9389 _aMartínez López, Joaquín _eHematología y Hemoterapia
245	0	0	_aAcute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF). _h[artículo]
260			_bCancer Cell International, _c2012
300			_a12(1):25.
500			_aFormato Vancouver: Ayala R, Martínez-López J, Gilsanz F. Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF). Cancer Cell Int. 2012 Jun 7;12(1):25.
501			_aPMID: 22676581
504			_aContiene 39 referencias
520			_aWe have investigated the role of erythroid transcription factors mRNA expression in patients with acute myeloid leukemia (AML) in the context of cytogenetic and other prognostic molecular markers, such as FMS-like Tyrosine Kinase 3 (FLT3), Nucleophosmin 1 (NPM1), and CCAAT/enhance-binding protein α (CEBPA) mutations. Further validation of Erythroid Krüppel-like Factor (EKLF) mRNA expression as a prognostic factor was assessed.We evaluated GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), EKLF and Myeloproliferative Leukemia virus oncogen homology (cMPL) gene mRNA expression in the bone marrow of 65 AML patients at diagnosis, and assessed any correlation with NPM1, FLT3 and CEBPA mutations. EKLF-positive AML was associated with lower WBC in peripheral blood (P = 0.049), a higher percentage of erythroblasts in bone marrow (p = 0.057), and secondary AMLs (P = 0.036). High expression levels of EKLF showed a trend to association with T-cell antigen expression, such as CD7 (P = 0.057). Patients expressing EKLF had longer Overall Survival (OS) and Event Free Survival (EFS) than those patients not expressing EKLF (median OS was 35.61 months and 19.31 months, respectively, P = 0.0241; median EFS was 19.80 months and 8.03 months, respectively, P = 0.0140). No correlation of GATA1, GATA2, EKLF and cMPL levels was observed with FLT-3 or NPM1 mutation status. Four of four CEBPA mutated AMLs were EKLF positive versus 10 of 29 CEBPA wild-type AMLs; three of the CEBPA mutated, EKLF-positive AMLs were also GATA2 positive. There were no cases of CEBPA mutations in the EKLF-negative AML group. In conclusion, we have validated EKLF mRNA expression as an independent predictor of outcome in AML, and its expression is not associated with FLT3-ITD and NPM1 mutations. EKLF mRNA expression in AML patients may correlate with dysregulated CEBPA.
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407786/ _yAcceso libre
942			_n0 _2ddc _cART
999			_c5595 _d5595